Blood Screening Market Size is Predicted to Witness 11.7% CAGR till 2030

The increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens are the key factors driving the growth of this market.The Blood Screening Market  is projected to reach USD 3.5 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 12.8%.Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042Market Segmentations:-Based on product & service, the Blood screening instruments market is segmented into reagents and kits, instruments, and software and services.

The reagents and kits segment accounted for the largest share of the blood screening market in 2019.

The large share of this segment can be attributed to the high consumption and repeated use of reagents & kits in blood screening procedures.

Also, the accessibility of a wide range of reagents and the need for reliable, specific, and fast detection of TTIs are driving the growth of the blood screening reagents & kits market.Based on end users, the blood screening market is segmented into blood banks and hospitals.

The blood bank segment accounted for the larger market share in 2019 and is projected to witness a higher growth rate during the forecast period.Recent Developments:-In September 2019, The US FDA approved cobas Babesia, Roche’s first whole-blood test for donor screening, in accordance with May 2019 FDA-updated industry guidance recommending screening and testing for Babesia.In February 2019, Grifols received FDA approval for the Procleix Babesia Assay for donor screening on its Procleix Panther System.In October 2016, Merck opened a new Life Science Center in Burlington, Massachusetts, to serve as a regional hub for scientific advancement and customer collaboration.Regional Analysis: Based on region, the Blood screening instruments market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

In 2019, North America accounted for the largest market share, followed by Europe.Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=267747042Key Players:- The prominent players operating in the Blood screening instruments market include Grifols (Spain), F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), BioMérieux (France), Bio-Rad Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US) ,Ortho Clinical Diagnostics, Inc.(US), Becton, Dickinson and Company (US), DiaSorin (Italy), GFE (Germany), Trinity Biotech (Ireland), Merck Millipore (Germany), GE Healthcare (US), Perkin Elmer (US), Bio-Techne Corporation (US), and J Mitra & Co. Pvt.

Blood Screening Market is anticipated to reach USD 3.9 billion by 2024.

It is anticipated to grow at a healthy rate in the years to come.

It helps to monitor health issues & diseases and a chronic ailments such as cancer and infections.

Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/blood-screening-market/request-sample Market Synopsis of Blood Screening Market:  The facts that propel the growth of the Market include surge in adoption of nucleic acid amplification test (NAT), increase in prevalence of infectious diseases, rise in awareness regarding healthcare, and increase in the number of blood donations.

Blood Screening Market may be analyzed based on technology, product outlook, end users, and geography.

The Market may be explored by technology as ELISA, Chemiluminescence Immunoassay (CLIA), and Enzyme Immunoassay (EIA), Nucleic Acid Amplification Test (NAT), Western Blotting, and Next-Generation Sequencing (NGS).

According to the latest research report published by Dhirtek Business Research, the global blood screening market report provides detailed information on the factors driving the growth of the blood screening market.

This pandemic is having an impact on various sectors of the economy.

It predicts that the global economy will suffer as a result of the loss of trillions of dollars.

To compete in a competitive market, the companies must identify product opportunities based on their strengths.

This study provides a platform for understanding the various exciting and rising prospects in the field of blood screening, and it will help every producer, distributor, or even user understand and succeed in this burgeoning industry.

Obtain a Sample Report and the Table of Content for the Blood Screening Market Report:https://www.dhirtekbusinessresearch.com/market-report/Blood-Screening-Market/request-for-sample-report Study Goals and Objectives of Global Blood Screening Market The report provides information on the market impact of blood screening.

Blood Screening Market: By Technology (Nucleic Acid Amplification Test, Enzyme-Linked Immunosorbent Assay, Next-Generation Sequencing), By Product and Services (Reagents, Instruments) and End User (Hospitals and Clinics) — Global Forecast till 2023Market Highlights:The Global Blood Screening Market is expected to register a growth of significant CAGR 9.8% during the forecast period (2018–2023).Blood screening is a medical process in which the blood is examined for the diagnosis of a specific diseased condition is known as blood screening.

Additionally, governments of various countries are in process to mandates testing all donated blood for several viruses.Avail a Free Sample@ https://www.medgadget.com/2020/09/blood-screening-market-2020-industry-covid-19-impact-forecast-by-size-share-estimation-growth-impact-healthcare-sector-insights-and-global-trends-analysis-to-2026.html Segmentation:The global blood screening market has been segmented on the devices, service providers, application, end users.On the basis of technology, the market has been classified as nucleic acid amplification test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, next-generation sequencing (NGS), western blotting.

The nucleic acid amplification test is segmented in to transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR).

The enzyme-linked immunosorbent assay is segmented in to ELISA market, by platform and ELISA market, by generation.

On the basis of end users, the market has been classified as hospitals, clinics, research institutes and academic centers, blood banks and others.Regional Analysis:The Americas is projected to lead the blood screening market in the forecast period.

Frequencies of blood screening are dramatically increasing over the last few years.

Recently published a report entitled Blood Screening Market projected till 2026, added by Value Market Research, covers key players along with their market share and strategic development adopted by them.

Further, the report provides market size, share, trends, outlook and forecast based on historical data coupled with drivers, restraints, and opportunities.The broad blood screening market has been sub-grouped into technology and product.

The report studies these subsets with respect to the geographical segmentation.

The strategists can gain a detailed insight and devise appropriate strategies to target specific market.

This detail will lead to a focused approach leading to identification of better opportunitiesRequest a FREE Sample Copy of Blood Screening Market Report with Full TOC At: https://www.valuemarketresearch.com/contact/blood-screening-market/download-sampleBy TechnologyNucleic Acid Amplification Test (NAT)ELISAChemiluminescence Immunoassay (CLIA)Enzyme Immunoassay (EIA)Next-Generation Sequencing (NGS)Western BlottingBy ProductReagentInstrumentThe report also covers detailed competitive landscape including company profiles of key players operating in the global market.

The key players in the blood screening market include Abbott Laboratories, Becton Dickinson and Company, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Grifols, Ortho-Clinical Diagnostics, Inc., Siemens Healthcare GmbH, SOFINA s.a (Biomérieux), And Thermo Fisher Scientific, Inc. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for blood screening in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Global Blood Screening Market is anticipated to reach USD 3.9 billion by 2024.

It is anticipated to grow at a healthy rate in the years to come.

Blood is a living tissue made up of liquid, with several proteins and cells suspended in it.

It offers nutrition and oxygen to the body cells through arteries, capillaries, and veins.

It helps to monitor health issues & diseases and a chronic ailments such as cancer and infections.The facts that propel the growth of the Market include surge in adoption of nucleic acid amplification test (NAT), increase in prevalence of infectious diseases, rise in awareness regarding healthcare, and increase in the number of blood donations.

The introduction of pathogen reduction technology and microbiology screening & multiplexing are anticipated to offer profitable opportunities for the blood screening market.

Blood Screening Market occurrences of new types of pathogens, increasing investment rates for advanced technology creation, growing geriatric population, and government’s favourable blood screening policies are likely to boost the growth of the blood screening market in the 2020-2027 forecast period.

On the other hand, increasing healthcare sector along with raising technological innovation will further fuel numerous opportunities which will lead to blood screening market growth in the forecast period mentioned above.

Get Sample Report at : https://www.databridgemarketresearch.com/request-a-sample/?dbmr=asia-pacific-blood-screening-marketCompetitive Analysis: Asia Pacific Blood Screening MarketFew of the major competitors currently working in Asia Pacific Blood Screening Market are Bio-Rad Laboratories, Inc. , Thermo Fisher Scientific Inc., BioMérieux SA, Beckman Coulter, Inc., Abbott , F. Hoffmann-La Roche Ltd , Cepheid , GRIFOLS INTERNATIONAL, S.A. , Siemens AG , Ortho Clinical Diagnostics , Immucor, Inc., Hologic Inc., among other domestic and Asia-Pacific players.

Key Pointers Covered in the Asia Pacific Blood Screening Market Trends and Forecast to 2026Asia Pacific   Blood Screening Market New Sales VolumesAsia Pacific   Blood Screening  Market Replacement Sales VolumesAsia Pacific   Blood Screening Market Installed BaseAsia Pacific   Blood Screening Market By BrandsAsia Pacific   Blood Screening Market SizeAsia Pacific   Blood Screening  Market Procedure VolumesAsia Pacific   Blood Screening Market Product Price AnalysisAsia Pacific   Blood Screening Market Healthcare OutcomesAsia Pacific   Blood Screening Market Cost of Care AnalysisAsia Pacific   Blood Screening Market Regulatory Framework and ChangesAsia Pacific   Blood Screening Market Prices and Reimbursement AnalysisAsia Pacific   Blood Screening Market Shares in Different RegionsRecent Developments for Asia Pacific   Blood Screening Market CompetitorsAsia Pacific   Blood Screening Market Upcoming ApplicationsAsia Pacific   Blood Screening Market Innovators StudyGet Detailed TOC:https://www.databridgemarketresearch.com/toc/?dbmr=asia-pacific-blood-screening-marketAsia-Pacific Blood Screening Market Scope and Market SizeBlood screening market is segmented on the basis of products & services, technology, disease type and end user.

The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.On the basis of product & services segment, the blood screening market is segmented into reagents and kits, instruments and software & services.

Instruments segment is further segmented into instruments, product types and instruments and purchase type.On the basis of technology the blood screening market is segmented into nucleic acid test, enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assay, next-generation sequencing (NGS) and others.

Global Blood Screening Market Forecast to 2027 encompasses crucial data about the global Blood Screening market and includes a thorough examination of technological development, market drivers, market share, market size, and regional segmentation.

The report also provides a comprehensive evaluation of the market trends, vital statistical data, accurate market estimations, and the key suppliers and manufacturers of the Blood Screening market.The report is also attuned with the currently ongoing COVID-19 pandemic and its effect on the key segments of the market.

The pandemic resulted in an economic slowdown and has directly affected the business sector by impacting the supply chains and availability of raw materials.

The report is updated with the impact of COVID-19 crisis, economic landscape, and present and future impact of COVID-19 on the market.

The report also aims to benefit the user by providing constructive data to gain insight into the market growth, size, and investment approaches.The key companies profiled in the market are: Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Ortho-Clinical Diagnostics, Inc., Grifols, Siemens Healthcare GmbH, SOFINA S.A, and Thermo Fisher Scientific.The report also covers a comprehensive analysis of the strategic alliances such as mergers and acquisitions, joint ventures, partnerships, collaborations, agreements, government and corporate deals, and product launches and brand promotions.

The report also offers a thorough analysis of the product portfolios, production capacity, gross margins, revenues, and costing of the key manufacturers and vendors.

The Global Blood Screening Market is estimated to grow at a CAGR of 9.8% during the forecast period.

On the basis of technology, the market has been classified as nucleic acid amplification test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, next-generation sequencing (NGS), western blotting.

The nucleic acid amplification test is segmented into transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR).

On the basis of products and services, the market has been classified as reagent and kits, enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides, and solutions, immunosorbents, instruments and software and services.The Americas is projected to lead the blood screening market in the forecast period.